Monopar Therapeutics Reports the Commencement of MNPR-101-Zr’s P-I Study for Treating Advanced Cancer
Shots:
- Monopar Therapeutics has initiated patient enrollment in the P-I study to investigate the safety and dosimetry of MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) among patients (n=12) with advanced cancer
- The study was based on the preclinical results demonstrating MNPR-101’s specific and durable tumor uptake in human cancer xenograft models. The data also showed the MNPR-101’s anti-tumor activity when combined with radioisotopes
- The company anticipates the expansion of the trial or a new trial to investigate the effectiveness of MNPR-101 linked with Ac-225 for advanced cancer treatment if it shows better tumor uptake, biodistribution and safety outcomes in the P-I study
Ref: Monopar Therapeutics | Image: Monopar Therapeutics
Related News:- Immix Biopharma Reports the Patient Dosing in P-Ib/IIa Trial of IMX-110 + Tislelizumab for the Treatment of Advanced Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
